Director, Pipeline & Product Communications

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Pipeline & Product Communications will lead pipeline and product communications strategy and execution for one or more RAS(ON) inhibitors or tumor types, supporting programs from early clinical development through regulatory milestones and pre-launch readiness. This role is responsible for shaping how tumor-specific pipeline and product narratives are communicated to external stakeholders, including scientific and medical audiences, patients and advocates, and industry media. Reporting to the Senior Director, Pipeline & Product Communications, this role will partner closely with cross-functional teams, including R&D, Medical Affairs, Regulatory, Commercial, Market Access, Patient Advocacy, Legal, and Corporate Communications, to ensure clear, consistent, and differentiated communications for the assigned tumor area. This is a high-impact role for a communications professional who combines scientific fluency with strong executional rigor and cross-functional collaboration. Key Responsibilities: Own pipeline and product communications for one or more RAS(ON) inhibitors or tumor types, ensuring clear differentiation, scientific credibility, and alignment with overall corporate and pipeline strategy. Lead communications execution for clinical milestones, including data readouts, abstracts, presentations, and major medical congresses. Partner with R&D and Medical Affairs to translate complex clinical and scientific data into clear, compelling external messaging tailored to the tumor-specific audience. Partner with affiliate communications teams in ex-U.S. markets to align on communications strategy and ensure globally consistent, locally relevant execution across key pipeline and product milestones. Support regulatory and pre-launch communications, including trial initiations, regulatory submissions, approvals, and launch readiness activities. Execute disease awareness and patient advocacy communications in partnership with Patient Advocacy, ensuring responsible education and inclusion of patient voice. Support communications related to value, access, and product-specific issues, in coordination with Market Access, Legal, and Corporate Communications. Contribute to scientific and medical thought leadership efforts, including congress presence, publication support, speaker positioning, and external engagement. In partnership with Corporate Communications, support earned media efforts for industry, trade, and scientific publications tied to tumor-specific milestones. Manage agency partners and external vendors supporting the tumor-specific communications program, ensuring quality execution and alignment with strategy. Track performance and apply insights to continuously improve communications effectiveness for the franchise. Required Skills, Experience, and Education: 10+ years of experience in biotech or pharmaceutical communications, including pipeline and product communications experience.Bachelor’s degree required in Communications or similar; advanced degree preferred. Demonstrated success supporting clinical development, regulatory milestones, and product launches, ideally in precision oncology or a similarly complex therapeutic area. Strong leadershi…